Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gen Sheng Wu

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Plos One|April 27, 2010
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cellsJing Xu, Jun-Ying Zhou, Wei-Zen Wei, et al.
Oncogene|February 11, 2025
Correction: Potential role for Cathepsin D in p53-dependent tumor suppression and chemosensitivityGen Sheng Wu, Paul Saftig, Christoph Peters, et al.
Cancer Research|February 7, 2007
Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycinJing Xu, Jun-Ying Zhou, Michael A Tainsky, et al.
Cancer Research|September 5, 2006
Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistanceZhaoqing Wang, Jing Xu, Jun-Ying Zhou, et al.
The Journal of Biological Chemistry|August 2, 2003
The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulationMaoxiang Li, Jun-Ying Zhou, Yubin Ge, et al.
Autophagy|July 27, 2016
Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagyJuan Wang, Jun-Ying Zhou, Dhonghyo Kho, et al.
Cancer Research|August 15, 2008
Sp1-mediated TRAIL induction in chemosensitizationJing Xu, Jun-Ying Zhou, Wei-Zen Wei, et al.
American Journal of Cancer Research|November 16, 2023
The role of the immune response and inflammatory pathways in TNF-related apoptosis-inducing ligand (TRAIL) resistance in triple-negative breast cancer cellsJulio M Pimentel, Jun-Ying Zhou, Seongho Kim, et al.
Oncotarget|April 21, 2017
ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cellsXun Yuan, Dhonghyo Kho, Jing Xu, et al.
Cancer Metastasis Reviews|March 16, 2018
Developing TRAIL/TRAIL death receptor-based cancer therapiesXun Yuan, Ambikai Gajan, Qian Chu, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Plos One|April 27, 2010
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cellsJing Xu, Jun-Ying Zhou, Wei-Zen Wei, et al.
Oncogene|February 11, 2025
Correction: Potential role for Cathepsin D in p53-dependent tumor suppression and chemosensitivityGen Sheng Wu, Paul Saftig, Christoph Peters, et al.
Cancer Research|February 7, 2007
Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycinJing Xu, Jun-Ying Zhou, Michael A Tainsky, et al.
Cancer Research|September 5, 2006
Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistanceZhaoqing Wang, Jing Xu, Jun-Ying Zhou, et al.
The Journal of Biological Chemistry|August 2, 2003
The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulationMaoxiang Li, Jun-Ying Zhou, Yubin Ge, et al.
Autophagy|July 27, 2016
Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagyJuan Wang, Jun-Ying Zhou, Dhonghyo Kho, et al.
Cancer Research|August 15, 2008
Sp1-mediated TRAIL induction in chemosensitizationJing Xu, Jun-Ying Zhou, Wei-Zen Wei, et al.
American Journal of Cancer Research|November 16, 2023
The role of the immune response and inflammatory pathways in TNF-related apoptosis-inducing ligand (TRAIL) resistance in triple-negative breast cancer cellsJulio M Pimentel, Jun-Ying Zhou, Seongho Kim, et al.
Oncotarget|April 21, 2017
ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cellsXun Yuan, Dhonghyo Kho, Jing Xu, et al.
Cancer Metastasis Reviews|March 16, 2018
Developing TRAIL/TRAIL death receptor-based cancer therapiesXun Yuan, Ambikai Gajan, Qian Chu, et al.
Pageof 7